Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Rights issue enables market expansion
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
Learn more …
PostPress Release
Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
Learn more …
PostNews
![BRAF Mutation](https://phiab.com/wp-content/uploads/2020/08/BRAF-Mutation-2.jpg)
New CEO commentary: “Understanding Skin Cancer”
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Learn more …
PostNews
![](https://phiab.com/wp-content/uploads/2018/07/Mold-Examination-1200x800.jpg)
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
Learn more …
PostNews
![App Suite Banner](https://phiab.com/wp-content/uploads/2018/07/AppSuite-banner-320x180.jpg)
PHI´s new software available for customer delivery
In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018.
Learn more …
PostPress Release
Kommuniké från extra bolagsstämma i Phase Holographic Imaging PHI AB (publ)
Igår, den 18 juni 2018, hölls extra bolagsstämma i Phase Holographic Imaging PHI AB (publ). Stämman röstande enhälligt för föreslagna beslut gällande nyemission.
Learn more …